Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment. / (Record no. 1201)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04347naa a22005777i 4500 |
| 001 - CONTROL NUMBER | |
| control field | UMUN-OA-20261005-MLS-059 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | local |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20261005174906.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr|||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 261005s2024 xx o u000 0 eng d |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.32604/or.2024.050350 |
| Source of number or code | doi |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (local)EuropePMC:PMC11209743 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | local |
| Language of cataloging | eng |
| Transcribing agency | local |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Paulina Chmiel |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment. / |
| Statement of responsibility, etc. | Paulina Chmiel; Aleksandra SłOWIKOWSKA; Łukasz Banaszek [and others]. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | [Place of publication not identified] : |
| Name of producer, publisher, distributor, manufacturer | Tech Science Press, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (1 article). |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 500 ## - GENERAL NOTE | |
| General note | Publication type: Review article. |
| 500 ## - GENERAL NOTE | |
| General note | Linked open-access copy: published version. |
| 506 0# - RESTRICTIONS ON ACCESS NOTE | |
| Terms governing access | Open access; no subscription required for the linked open-access version. |
| Standardized terminology for access restriction | Unrestricted online access |
| Source of term | star |
| 520 3# - SUMMARY, ETC. | |
| Summary, etc. | Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy. |
| 540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE | |
| Terms governing use and reproduction | Creative Commons Attribution. See the linked licence for the applicable terms. |
| Uniform Resource Identifier | <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a> |
| 546 ## - LANGUAGE NOTE | |
| Language note | In English. |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Course allocation: B. Sc. Medical Laboratory Science. |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Anaplastic Lymphoma Kinase (Alk) |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Inflammatory Myofibroblastic Tumor (Imt) |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Tyrosine Kinase Inhibitors (Tki) |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Epithelioid Inflammatory Myofibroblastic Sarcoma |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | B. Sc. Medical Laboratory Science |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | UMUN open access collection |
| 653 ## - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | molecular diagnostics |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Review articles. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Aleksandra SłOWIKOWSKA |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Łukasz Banaszek |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Anna Szumera-CIEćKIEWICZ |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | BARTłOMIEJ Szostakowski |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mateusz J SPAłEK |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tomasz Świtaj |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Piotr Rutkowski |
| Relator term | author. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Anna M Czarnecka |
| Relator term | author. |
| 773 0# - HOST ITEM ENTRY | |
| Title | Oncology research |
| Related parts | Vol. 32, no. 7, (2024), pages/article 1141-1162 |
| International Standard Serial Number | 0965-0407 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://europepmc.org/articles/PMC11209743">https://europepmc.org/articles/PMC11209743</a> |
| Link text | Read open-access publication |
| Public note | Open access. |
| Access status | 0 |
| 884 ## - DESCRIPTION CONVERSION INFORMATION | |
| Conversion process | Course selection and automated MARC21 enrichment from Europe PMC metadata. |
| Conversion date | 20261005 |
| Identifier of source metadata | https://europepmc.org/articles/PMC11209743 |
| Conversion agency | local |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Suppress in OPAC | No |
No items available.